An increase in deoxycholic acid, and concomitant decreases in FXR-agonistic chenodeoxycholic acid, are also reported in patients with MASLD, indicating the importance of the bile acid–FXR axis [139]. The gene discussed is NR1H4; the disease is metabolic dysfunction-associated steatotic liver disease.